|
|
|||||||||||||||||||||||||||||||||||||||||||||||
By The Online Investor Staff, updated Fri., May. 24, 5:05 PM
|
||||||||||||||||||||||||||||||||||||||||||||||||
Secondary Stock Offerings| This Slide: #12 of 25 |
Slide #12. Ironwood Pharmaceuticals, Inc. — Secondary Offering
Company:
Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD)
Date announced:
5/20/2013
Shares Offered:
10,500,000
Date of Pricing:
5/21/2013
Price Per Share:
$13.00
Secondary Offering Details:
Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) today announced that it has commenced an underwritten public offering of 10,500,000 shares of its Class A common stock. All of the shares are being offered by Ironwood. The Company will grant the underwriters a 30-day option to purchase up to an additional 1,575,000 shares in connection with the offering. -- Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) today announced the pricing of an underwritten public offering of 10,500,000 shares of its Class A common stock at a price of $13.00 per share to the public. All of the shares are being offered by Ironwood. The gross proceeds to Ironwood from this offering are expected to be approximately $136.5 million, before deducting underwriting discounts and commissions, and other estimated offering expenses payable by Ironwood. The offering is expected to close on May 24, 2013, subject to the satisfaction of customary closing conditions.
Ironwood Pharmaceuticals is engaged in discovering and developing medicines. Co.'s lead product candidate is linaclotide, a guanylate cyclase type-C agonist being developed for the treatment of patients with irritable bowel syndrome with constipation and chronic constipation. Co. also has several early development candidates in several therapeutic areas, including gastrointestinal disease, central nervous system disorders and respiratory disease, including IW-9179, which is in early development for the treatment of painful gastrointestinal disorders of the small intestine such as dyspepsia and gastroparesis.
Open the IRWD Page at The Online Investor »
|
|||||||||||||||||||||
Open the IRWD Page at The Online Investor (in a new window) »
|
Trade IRWD Now: |
Avg. Broker Rec.
|
Hold (2.00 out of 4) 11st percentile
(ranked lower than approx. 89% of all stocks covered)
Based on Zacks ABR data; powered by Xignite |
Secondary Stock Offerings | www.TheOnlineInvestor.com | Copyright © 1998 - 2013, All Rights Reserved
Nothing in The Online Investor is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Service. Video widget and stock market videos powered by Market News Video. Quote data delayed at least 20 minutes, powered by Ticker Technologies, and Mergent. Contact The Online Investor; Meet Our Editorial Staff.